(SYNH) – StreetInsider.com Reports
-
Syneos Health (SYNH) Appoints Colin Shannon as CEO
-
Civitas Resources to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600
-
Syneos Health (SYNH) Appoints Terttu Haring as President, Clinical Sites & Patients
-
Syneos Health (SYNH) and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity
-
Syneos Health (SYNH) and Star Parent Announce Proposed $1.70B Notes Offering
-
Syneos Health (SYNH) Stockholders Approve Agreement with Private Investment Consortium
-
Syneos (SYNH) PT Raised to $43 at Mizuho Securities
-
Syneos (SYNH) PT Raised to $43 at Mizuho Securities
-
Deutsche Bank Downgrades Syneos (SYNH) to Hold
-
Barclays Upgrades Syneos (SYNH) to Equalweight
-
Baird Downgrades Syneos (SYNH) to Neutral
-
Syneos (SYNH) PT Raised to $43 at Evercore ISI
-
JPMorgan Upgrades Syneos (SYNH) to Neutral
-
Airbnb, Twilio and Virgin Galactic fall premarket; Rivian rises
-
Elliott, Patient Square and Veritas acquire Syneos Health (SYNH) in $7.1B Deal
-
Syneos Health (SYNH) Tops Q1 EPS by 9c
-
Syneos taken private for $4.46 billion by investment consortium
-
Syneos Health (SYNH) Acquired by Investment Consortium for $43/sh or $7.1B Cash
-
After-hours movers: Syneos gains on deal talk; Twilio, Airbnb fall following EPS
-
Elliott, Patient Square, Veritas Said To Near Deal For Syneos (SYNH) - Bloomberg
-
Syneos Health (SYNH) Appoints Michael Bonello as CFO
-
Syneos Health (SYNH) gains on M&A highlight
-
Syneos (SYNH) PT Lowered to $37 at Barclays
-
Syneos Health (SYNH) Appoints Stanford Rudnick as Interim CFO
-
Syneos Health (SYNH) Launches Medical Affairs Digital Amplifier
-
Syneos (SYNH) PT Lowered to $48 at Baird
-
Creative Medical Technology (CELZ) Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
-
Syneos (SYNH) PT Raised to $45 at Barclays
-
Syneos Health (SYNH) working on a sale - Reuters
-
Syneos Health (SYNH) Halted on Volatility, Up 7%
-
Syneos (SYNH) PT Raised to $40 at UBS
-
Syneos Health (SYNH) on watch on rumors
-
Syneos (SYNH) PT Raised to $51 at Baird
-
Syneos (SYNH) PT Raised to $37 at Evercore ISI
-
Syneos Health (SYNH) Tops Q4 EPS by 2c; Guides FY23 Below the Street
-
JPMorgan Downgrades Syneos (SYNH) to Underweight, 'Little Visibility into 2023 Clinical Improvement'
-
Syneos Health (SYNH) and Haystack Health Partner to Accelerate Clinical Trials with AI
-
Cryoport (CYRX) Announces New Strategic Partnership with Syneos Health (SYNH)
-
Barclays Downgrades Syneos (SYNH) to Underweight
-
Syneos Health (SYNH) Partners with Fosun USA to Launch Serplulimab
-
Syneos Health (SYNH) Announces CFO Transition
-
Mizuho Securities Downgrades Syneos (SYNH) to Neutral
-
Syneos (SYNH) PT Lowered to $51 at Deutsche Bank
-
Syneos (SYNH) PT Lowered to $34 at UBS
-
Syneos (SYNH) PT Lowered to $30 at Barclays
-
Syneos (SYNH) PT Lowered to $30 at Citi
-
UPDATE: JPMorgan Downgrades Syneos (SYNH) to Neutral
-
Syneos (SYNH) PT Lowered to $77 at Deutsche Bank
-
Syneos (SYNH) PT Lowered to $66 at Mizuho Securities
-
Syneos (SYNH) PT Lowered to $60 at Barclays
Back to SYNH Stock Lookup